Global Pharmacogenomics Technology/Therapeutic Diagnosis/Companion Diagnosis (CDx) Market Research Report, Competitive, Technology and Forecast Analysis 2025-2032
Description
Market Overview
According to DIResearch＇s in-depth investigation and research, the global Pharmacogenomics Technology/Therapeutic Diagnosis/Companion Diagnosis (CDx) market size will reach Million USD in 2025 and is projected to reach Million USD by 2032, with a CAGR of % (2025-2032). Notably, the China Pharmacogenomics Technology/Therapeutic Diagnosis/Companion Diagnosis (CDx) market has changed rapidly in the past few years. By 2025, China＇s market size is expected to be Million USD, representing approximately % of the global market share.
Research Summary
Pharmacogenomics technology, also known as therapeutic diagnosis or companion diagnosis (CDx), involves the use of genetic information to personalize medical treatments, particularly in the field of drug prescription. It focuses on understanding how an individual＇s genetic makeup influences their response to medications. By analyzing genetic variations, such as single nucleotide polymorphisms (SNPs), pharmacogenomics aims to identify patients who are more likely to respond positively to a specific treatment, those who may experience adverse reactions, and individuals who may not respond effectively to certain drugs. Companion diagnostics play a crucial role in tailoring treatment plans, allowing healthcare providers to make more informed decisions about drug selection, dosage, and potential side effects based on a patient＇s genetic profile. This approach enhances the efficacy and safety of medical treatments, providing a more personalized and targeted approach to healthcare.
The major global suppliers of Pharmacogenomics Technology/Therapeutic Diagnosis/Companion Diagnosis (CDx) include Qiagen, GE Healthcare, Agilent Technologies, F Hoffman La Roche, Foundation Medicine, Thermo Fisher Scientific, Leica Biosystems Nussloch, Pfizer, etc. The global players competition landscape in this report is divided into three tiers. The first tier comprises global leading enterprises that command a substantial market share, hold a dominant industry position, possess strong competitiveness and influence, and generate significant revenue. The second tier includes companies with a notable market presence and reputation; these firms actively follow industry leaders in product, service, or technological innovation and maintain a moderate revenue scale. The third tier consists of smaller companies with limited market share and lower brand recognition, primarily focused on local markets and generating comparatively lower revenue.
This report studies the market size, price trends and future development prospects of Pharmacogenomics Technology/Therapeutic Diagnosis/Companion Diagnosis (CDx). Focus on analysing the market share, product portfolio, prices, sales, revenue and gross profit margin of global major suppliers, as well as the market status and trends of different product types and applications in the global Pharmacogenomics Technology/Therapeutic Diagnosis/Companion Diagnosis (CDx) market. The report data covers historical data from 2020 to 2024, based year in 2025 and forecast data from 2026 to 2032.
The regions and countries in the report include US, Germany, Japan, China, France, UK, South Korea, Canada, Italy, Russia, Mexico, Brazil, India, Vietnam, Thailand, South Africa and other regions, covering the Pharmacogenomics Technology/Therapeutic Diagnosis/Companion Diagnosis (CDx) market conditions and future development trends of key regions and countries, combined with industry-related policies and the latest technological developments, analyze the development characteristics of Pharmacogenomics Technology/Therapeutic Diagnosis/Companion Diagnosis (CDx) industries in various regions and countries, help companies understand the development characteristics of each region, help companies formulate business strategies, and achieve the ultimate goal of the company's global development strategy.
The data sources of this report mainly include the National Bureau of Statistics, customs databases, industry associations, corporate financial reports, third-party databases, etc. Among them, macroeconomic data mainly comes from the National Bureau of Statistics, International Economic Research Organization; industry statistical data mainly come from industry associations; company data mainly comes from interviews, public information collection, third-party reliable databases, and price data mainly comes from various markets monitoring database.
Global Key Suppliers of Pharmacogenomics Technology/Therapeutic Diagnosis/Companion Diagnosis (CDx) Include:
Qiagen
GE Healthcare
Agilent Technologies
F Hoffman La Roche
Foundation Medicine
Thermo Fisher Scientific
Leica Biosystems Nussloch
Pfizer
Pharmacogenomics Technology/Therapeutic Diagnosis/Companion Diagnosis (CDx) Product Segment Include:
PCR
In-situ Hybridization
Immunohistochemistry
Sequencing
Others
Pharmacogenomics Technology/Therapeutic Diagnosis/Companion Diagnosis (CDx) Product Application Include:
Oncology
Neurological Disorders
Cardiovascular Disease
Immunological Disorders
Others
Chapter Scope
Chapter 1: Product Research Range, Product Types and Applications, Market Overview, Market Situation and Trend
Chapter 2: Global Pharmacogenomics Technology/Therapeutic Diagnosis/Companion Diagnosis (CDx) Industry PESTEL Analysis
Chapter 3: Global Pharmacogenomics Technology/Therapeutic Diagnosis/Companion Diagnosis (CDx) Industry Porter's Five Forces Analysis
Chapter 4: Global Pharmacogenomics Technology/Therapeutic Diagnosis/Companion Diagnosis (CDx) Major Regional Market Size (Revenue) and Forecast Analysis
Chapter 5: Global Pharmacogenomics Technology/Therapeutic Diagnosis/Companion Diagnosis (CDx) Competitive Analysis of Key Suppliers (Revenue, Market Share, Regional Distribution and Industry Concentration)
Chapter 6: Global Pharmacogenomics Technology/Therapeutic Diagnosis/Companion Diagnosis (CDx) Revenue and Forecast Analysis by Product Type
Chapter 7: Key Company Profiles (Product Portfolio, Revenue and Gross Margin)
Chapter 8: Industrial Chain Analysis, Pharmacogenomics Technology/Therapeutic Diagnosis/Companion Diagnosis (CDx) Different Application Market Analysis (Revenue and Forecast) and Sales Channel Analysis
Chapter 9: Research Findings and Conclusion
Chapter 10: Methodology and Data Sources
According to DIResearch＇s in-depth investigation and research, the global Pharmacogenomics Technology/Therapeutic Diagnosis/Companion Diagnosis (CDx) market size will reach Million USD in 2025 and is projected to reach Million USD by 2032, with a CAGR of % (2025-2032). Notably, the China Pharmacogenomics Technology/Therapeutic Diagnosis/Companion Diagnosis (CDx) market has changed rapidly in the past few years. By 2025, China＇s market size is expected to be Million USD, representing approximately % of the global market share.
Research Summary
Pharmacogenomics technology, also known as therapeutic diagnosis or companion diagnosis (CDx), involves the use of genetic information to personalize medical treatments, particularly in the field of drug prescription. It focuses on understanding how an individual＇s genetic makeup influences their response to medications. By analyzing genetic variations, such as single nucleotide polymorphisms (SNPs), pharmacogenomics aims to identify patients who are more likely to respond positively to a specific treatment, those who may experience adverse reactions, and individuals who may not respond effectively to certain drugs. Companion diagnostics play a crucial role in tailoring treatment plans, allowing healthcare providers to make more informed decisions about drug selection, dosage, and potential side effects based on a patient＇s genetic profile. This approach enhances the efficacy and safety of medical treatments, providing a more personalized and targeted approach to healthcare.
The major global suppliers of Pharmacogenomics Technology/Therapeutic Diagnosis/Companion Diagnosis (CDx) include Qiagen, GE Healthcare, Agilent Technologies, F Hoffman La Roche, Foundation Medicine, Thermo Fisher Scientific, Leica Biosystems Nussloch, Pfizer, etc. The global players competition landscape in this report is divided into three tiers. The first tier comprises global leading enterprises that command a substantial market share, hold a dominant industry position, possess strong competitiveness and influence, and generate significant revenue. The second tier includes companies with a notable market presence and reputation; these firms actively follow industry leaders in product, service, or technological innovation and maintain a moderate revenue scale. The third tier consists of smaller companies with limited market share and lower brand recognition, primarily focused on local markets and generating comparatively lower revenue.
This report studies the market size, price trends and future development prospects of Pharmacogenomics Technology/Therapeutic Diagnosis/Companion Diagnosis (CDx). Focus on analysing the market share, product portfolio, prices, sales, revenue and gross profit margin of global major suppliers, as well as the market status and trends of different product types and applications in the global Pharmacogenomics Technology/Therapeutic Diagnosis/Companion Diagnosis (CDx) market. The report data covers historical data from 2020 to 2024, based year in 2025 and forecast data from 2026 to 2032.
The regions and countries in the report include US, Germany, Japan, China, France, UK, South Korea, Canada, Italy, Russia, Mexico, Brazil, India, Vietnam, Thailand, South Africa and other regions, covering the Pharmacogenomics Technology/Therapeutic Diagnosis/Companion Diagnosis (CDx) market conditions and future development trends of key regions and countries, combined with industry-related policies and the latest technological developments, analyze the development characteristics of Pharmacogenomics Technology/Therapeutic Diagnosis/Companion Diagnosis (CDx) industries in various regions and countries, help companies understand the development characteristics of each region, help companies formulate business strategies, and achieve the ultimate goal of the company's global development strategy.
The data sources of this report mainly include the National Bureau of Statistics, customs databases, industry associations, corporate financial reports, third-party databases, etc. Among them, macroeconomic data mainly comes from the National Bureau of Statistics, International Economic Research Organization; industry statistical data mainly come from industry associations; company data mainly comes from interviews, public information collection, third-party reliable databases, and price data mainly comes from various markets monitoring database.
Global Key Suppliers of Pharmacogenomics Technology/Therapeutic Diagnosis/Companion Diagnosis (CDx) Include:
Qiagen
GE Healthcare
Agilent Technologies
F Hoffman La Roche
Foundation Medicine
Thermo Fisher Scientific
Leica Biosystems Nussloch
Pfizer
Pharmacogenomics Technology/Therapeutic Diagnosis/Companion Diagnosis (CDx) Product Segment Include:
PCR
In-situ Hybridization
Immunohistochemistry
Sequencing
Others
Pharmacogenomics Technology/Therapeutic Diagnosis/Companion Diagnosis (CDx) Product Application Include:
Oncology
Neurological Disorders
Cardiovascular Disease
Immunological Disorders
Others
Chapter Scope
Chapter 1: Product Research Range, Product Types and Applications, Market Overview, Market Situation and Trend
Chapter 2: Global Pharmacogenomics Technology/Therapeutic Diagnosis/Companion Diagnosis (CDx) Industry PESTEL Analysis
Chapter 3: Global Pharmacogenomics Technology/Therapeutic Diagnosis/Companion Diagnosis (CDx) Industry Porter's Five Forces Analysis
Chapter 4: Global Pharmacogenomics Technology/Therapeutic Diagnosis/Companion Diagnosis (CDx) Major Regional Market Size (Revenue) and Forecast Analysis
Chapter 5: Global Pharmacogenomics Technology/Therapeutic Diagnosis/Companion Diagnosis (CDx) Competitive Analysis of Key Suppliers (Revenue, Market Share, Regional Distribution and Industry Concentration)
Chapter 6: Global Pharmacogenomics Technology/Therapeutic Diagnosis/Companion Diagnosis (CDx) Revenue and Forecast Analysis by Product Type
Chapter 7: Key Company Profiles (Product Portfolio, Revenue and Gross Margin)
Chapter 8: Industrial Chain Analysis, Pharmacogenomics Technology/Therapeutic Diagnosis/Companion Diagnosis (CDx) Different Application Market Analysis (Revenue and Forecast) and Sales Channel Analysis
Chapter 9: Research Findings and Conclusion
Chapter 10: Methodology and Data Sources
Table of Contents
165 Pages
- 1 Pharmacogenomics Technology/Therapeutic Diagnosis/Companion Diagnosis (CDx) Market Overview
- 1.1 Product Definition and Statistical Scope
- 1.2 Pharmacogenomics Technology/Therapeutic Diagnosis/Companion Diagnosis (CDx) Product by Type
- 1.2.1 PCR
- 1.2.2 In-situ Hybridization
- 1.2.3 Immunohistochemistry
- 1.2.4 Sequencing
- 1.2.5 Others
- 1.3 Pharmacogenomics Technology/Therapeutic Diagnosis/Companion Diagnosis (CDx) Product by Application
- 1.3.1 Oncology
- 1.3.2 Neurological Disorders
- 1.3.3 Cardiovascular Disease
- 1.3.4 Immunological Disorders
- 1.3.5 Others
- 1.4 Global Pharmacogenomics Technology/Therapeutic Diagnosis/Companion Diagnosis (CDx) Market Size Analysis (2020-2032)
- 1.5 Pharmacogenomics Technology/Therapeutic Diagnosis/Companion Diagnosis (CDx) Market Development Status and Trends
- 1.5.1 Pharmacogenomics Technology/Therapeutic Diagnosis/Companion Diagnosis (CDx) Industry Development Status Analysis
- 1.5.2 Pharmacogenomics Technology/Therapeutic Diagnosis/Companion Diagnosis (CDx) Industry Development Trends Analysis
- 2 Pharmacogenomics Technology/Therapeutic Diagnosis/Companion Diagnosis (CDx) Market PESTEL Analysis
- 2.1 Political Factors Analysis
- 2.2 Economic Factors Analysis
- 2.3 Social Factors Analysis
- 2.4 Technological Factors Analysis
- 2.5 Environmental Factors Analysis
- 2.6 Legal Factors Analysis
- 3 Pharmacogenomics Technology/Therapeutic Diagnosis/Companion Diagnosis (CDx) Market Porter's Five Forces Analysis
- 3.1 Competitive Rivalry
- 3.2 Threat of New Entrants
- 3.3 Bargaining Power of Suppliers
- 3.4 Bargaining Power of Buyers
- 3.5 Threat of Substitutes
- 4 Global Pharmacogenomics Technology/Therapeutic Diagnosis/Companion Diagnosis (CDx) Market Analysis by Country
- 4.1 Global Pharmacogenomics Technology/Therapeutic Diagnosis/Companion Diagnosis (CDx) Market Size Analysis by Country: 2024 VS 2025 VS 2032
- 4.1.1 Global Pharmacogenomics Technology/Therapeutic Diagnosis/Companion Diagnosis (CDx) Revenue Analysis by Country (2020-2025)
- 4.1.2 Global Pharmacogenomics Technology/Therapeutic Diagnosis/Companion Diagnosis (CDx) Revenue Forecast Analysis by Country (2026-2032)
- 4.2 United States Pharmacogenomics Technology/Therapeutic Diagnosis/Companion Diagnosis (CDx) Market Revenue and Growth Rate (2020-2032)
- 4.3 Germany Pharmacogenomics Technology/Therapeutic Diagnosis/Companion Diagnosis (CDx) Market Revenue and Growth Rate (2020-2032)
- 4.4 Japan Pharmacogenomics Technology/Therapeutic Diagnosis/Companion Diagnosis (CDx) Market Revenue and Growth Rate (2020-2032)
- 4.5 China Pharmacogenomics Technology/Therapeutic Diagnosis/Companion Diagnosis (CDx) Market Revenue and Growth Rate (2020-2032)
- 4.6 France Pharmacogenomics Technology/Therapeutic Diagnosis/Companion Diagnosis (CDx) Market Revenue and Growth Rate (2020-2032)
- 4.7 U.K. Pharmacogenomics Technology/Therapeutic Diagnosis/Companion Diagnosis (CDx) Market Revenue and Growth Rate (2020-2032)
- 4.8 South Korea Pharmacogenomics Technology/Therapeutic Diagnosis/Companion Diagnosis (CDx) Market Revenue and Growth Rate (2020-2032)
- 4.9 Canada Pharmacogenomics Technology/Therapeutic Diagnosis/Companion Diagnosis (CDx) Market Revenue and Growth Rate (2020-2032)
- 4.10 Italy Pharmacogenomics Technology/Therapeutic Diagnosis/Companion Diagnosis (CDx) Market Revenue and Growth Rate (2020-2032)
- 4.11 Russia Pharmacogenomics Technology/Therapeutic Diagnosis/Companion Diagnosis (CDx) Market Revenue and Growth Rate (2020-2032)
- 4.12 Mexico Pharmacogenomics Technology/Therapeutic Diagnosis/Companion Diagnosis (CDx) Market Revenue and Growth Rate (2020-2032)
- 4.13 Brazil Pharmacogenomics Technology/Therapeutic Diagnosis/Companion Diagnosis (CDx) Market Revenue and Growth Rate (2020-2032)
- 4.14 India Pharmacogenomics Technology/Therapeutic Diagnosis/Companion Diagnosis (CDx) Market Revenue and Growth Rate (2020-2032)
- 4.15 Vietnam Pharmacogenomics Technology/Therapeutic Diagnosis/Companion Diagnosis (CDx) Market Revenue and Growth Rate (2020-2032)
- 4.16 Thailand Pharmacogenomics Technology/Therapeutic Diagnosis/Companion Diagnosis (CDx) Market Revenue and Growth Rate (2020-2032)
- 4.17 South Africa Pharmacogenomics Technology/Therapeutic Diagnosis/Companion Diagnosis (CDx) Market Revenue and Growth Rate (2020-2032)
- 5 Competition by Suppliers
- 5.1 Global Pharmacogenomics Technology/Therapeutic Diagnosis/Companion Diagnosis (CDx) Market Revenue by Key Suppliers (2021-2025)
- 5.2 Pharmacogenomics Technology/Therapeutic Diagnosis/Companion Diagnosis (CDx) Competitive Landscape Analysis and Market Dynamic
- 5.2.1 Pharmacogenomics Technology/Therapeutic Diagnosis/Companion Diagnosis (CDx) Competitive Landscape Analysis
- 5.2.2 Global Key Suppliers Headquarter and Key Area Sales
- 5.2.3 Market Dynamic
- 6 Pharmacogenomics Technology/Therapeutic Diagnosis/Companion Diagnosis (CDx) Market Analysis by Type
- 6.1 Global Pharmacogenomics Technology/Therapeutic Diagnosis/Companion Diagnosis (CDx) Market Size Analysis by Type: 2024 VS 2025 VS 2032
- 6.2 Global Pharmacogenomics Technology/Therapeutic Diagnosis/Companion Diagnosis (CDx) Revenue and Forecast Analysis by Type (2020-2032)
- 7 Key Companies Analysis
- 7.1 Qiagen
- 7.1.1 Qiagen Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.1.2 Qiagen Pharmacogenomics Technology/Therapeutic Diagnosis/Companion Diagnosis (CDx) Product Portfolio
- 7.1.3 Qiagen Pharmacogenomics Technology/Therapeutic Diagnosis/Companion Diagnosis (CDx) Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.2 GE Healthcare
- 7.2.1 GE Healthcare Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.2.2 GE Healthcare Pharmacogenomics Technology/Therapeutic Diagnosis/Companion Diagnosis (CDx) Product Portfolio
- 7.2.3 GE Healthcare Pharmacogenomics Technology/Therapeutic Diagnosis/Companion Diagnosis (CDx) Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.3 Agilent Technologies
- 7.3.1 Agilent Technologies Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.3.2 Agilent Technologies Pharmacogenomics Technology/Therapeutic Diagnosis/Companion Diagnosis (CDx) Product Portfolio
- 7.3.3 Agilent Technologies Pharmacogenomics Technology/Therapeutic Diagnosis/Companion Diagnosis (CDx) Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.4 F Hoffman La Roche
- 7.4.1 F Hoffman La Roche Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.4.2 F Hoffman La Roche Pharmacogenomics Technology/Therapeutic Diagnosis/Companion Diagnosis (CDx) Product Portfolio
- 7.4.3 F Hoffman La Roche Pharmacogenomics Technology/Therapeutic Diagnosis/Companion Diagnosis (CDx) Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.5 Foundation Medicine
- 7.5.1 Foundation Medicine Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.5.2 Foundation Medicine Pharmacogenomics Technology/Therapeutic Diagnosis/Companion Diagnosis (CDx) Product Portfolio
- 7.5.3 Foundation Medicine Pharmacogenomics Technology/Therapeutic Diagnosis/Companion Diagnosis (CDx) Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.6 Thermo Fisher Scientific
- 7.6.1 Thermo Fisher Scientific Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.6.2 Thermo Fisher Scientific Pharmacogenomics Technology/Therapeutic Diagnosis/Companion Diagnosis (CDx) Product Portfolio
- 7.6.3 Thermo Fisher Scientific Pha
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
